These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26365310)

  • 1. LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.
    Choi I; Kim B; Byun JW; Baik SH; Huh YH; Kim JH; Mook-Jung I; Song WK; Shin JH; Seo H; Suh YH; Jou I; Park SM; Kang HC; Joe EH
    Nat Commun; 2015 Sep; 6():8255. PubMed ID: 26365310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity.
    Ho DH; Seol W; Eun JH; Son IH
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1088-1094. PubMed ID: 27914807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
    Ho DH; Kim H; Kim J; Sim H; Ahn H; Kim J; Seo H; Chung KC; Park BJ; Son I; Seol W
    Mol Brain; 2015 Sep; 8():54. PubMed ID: 26384650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 Inhibits FAK Activity by Promoting FERM-mediated Autoinhibition of FAK and Recruiting the Tyrosine Phosphatase, SHP-2.
    Choi I; Byun JW; Park SM; Jou I; Joe EH
    Exp Neurobiol; 2016 Oct; 25(5):269-276. PubMed ID: 27790061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
    Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
    Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein.
    Marker DF; Puccini JM; Mockus TE; Barbieri J; Lu SM; Gelbard HA
    J Neuroinflammation; 2012 Nov; 9():261. PubMed ID: 23190742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.
    Puccini JM; Marker DF; Fitzgerald T; Barbieri J; Kim CS; Miller-Rhodes P; Lu SM; Dewhurst S; Gelbard HA
    J Neurosci; 2015 Apr; 35(13):5271-83. PubMed ID: 25834052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of microglial diversity in a LRRK2 G2019S mouse model of Parkinson's disease.
    Iovino L; VanderZwaag J; Kaur G; Khakpour M; Giusti V; Donadon M; Chiavegato A; Tenorio-Lopes L; Greggio E; Tremblay ME; Civiero L
    Neurobiol Dis; 2024 Jun; 195():106481. PubMed ID: 38527708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.
    Shanley MR; Hawley D; Leung S; Zaidi NF; Dave R; Schlosser KA; Bandopadhyay R; Gerber SA; Liu M
    Biochemistry; 2015 Aug; 54(33):5198-208. PubMed ID: 26268594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
    Su YC; Qi X
    Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Gillardon F
    J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
    Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
    PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.